Related Experiment Video
Updated: Jul 27, 2025
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
ASCRS clinical advisory on intracameral moxifloxacin injection for infection prophylaxis
William G Myers1, David F Chang, Neal H Shorstein
1From the Northwestern University, Chicago, Illinois (Myers); University of California, San Francisco, San Francisco, California (Chang); Kaiser Permanente, Walnut Creek, California (Shorstein); Scripps Clinic Medical Group, La Jolla, California (Mah); Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, Salt Lake City, Utah (Mamalis); Stein Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California (Miller).
Abstract:
Moxifloxacin solution is frequently injected at the conclusion of cataract surgery for endophthalmitis prophylaxis. 2 different concentrations are most commonly available in the United States for intracameral (IC) use: 0.5% (5 mg/mL) and 0.1% (1 mg/mL). The recommended volume to be injected is different for the 2 concentrations, and incorrect dosing can increase the risk of toxic anterior segment syndrome or endophthalmitis. In addition, the U.S. Food and Drug Administration recently published an alert regarding potential adverse events associated with intraocular compounded moxifloxacin. This clinical advisory reviews the optimal dosing of IC moxifloxacin based on current evidence.
Insights
Proper dosing of intracameral (IC) moxifloxacin is crucial after cataract surgery to prevent endophthalmitis. This advisory clarifies optimal IC moxifloxacin volumes for common concentrations, reducing risks like toxic anterior segment syndrome.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Moxifloxacin solution is commonly administered intracameral (IC) post-cataract surgery for endophthalmitis prophylaxis.
- Two primary concentrations (0.5% and 0.1%) are available in the U.S. for IC use.
- Incorrect dosing of IC moxifloxacin can elevate risks of toxic anterior segment syndrome and endophthalmitis.
Purpose of the Study:
- To review current evidence on optimal dosing strategies for intracameral (IC) moxifloxacin.
- To provide guidance on correct moxifloxacin volumes for different concentrations used in ophthalmic surgery.
Main Methods:
- Review of current clinical evidence and guidelines regarding IC moxifloxacin administration.
- Analysis of recommended volumes for 0.5% and 0.1% moxifloxacin concentrations.
Main Results:
- Different injection volumes are recommended for the 0.5% (5 mg/mL) and 0.1% (1 mg/mL) moxifloxacin solutions.
- Adherence to specific volumes is critical for efficacy and safety.
Conclusions:
- Optimal dosing of IC moxifloxacin is essential for effective endophthalmitis prophylaxis.
- Accurate volume administration minimizes the risk of adverse events, including toxic anterior segment syndrome.
Related Concept Videos
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment